Company Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
The company was founded in 2007 and is headquartered in San Diego, California.
Country | United States |
Founded | 2007 |
IPO Date | Dec 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 65 |
CEO | Dr. Jay M. Short Ph.D. |
Contact Details
Address: 11085 Torreyana Road San Diego, California 92121 United States | |
Phone | 858-558-0708 |
Website | bioatla.com |
Stock Details
Ticker Symbol | BCAB |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001826892 |
CUSIP Number | 09077B104 |
ISIN Number | US09077B1044 |
Employer ID | 85-1922320 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
Richard A. Waldron | Senior Vice President and Chief Financial Officer |
Dr. Eric L. Sievers M.D. | Chief Medical Officer |
Christian J. Vasquez | Chief Accounting Officer, Controller and Corporate Secretary |
Susie Melody | Senior Vice President of Human Resources |
Dr. Cathy Chang Ph.D. | Senior Vice President of Research and Development |
Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
Monica Sullivan | Senior Vice President of Intellectual Property and Contracts |
Sheri Lydick | Chief Commercial Officer |
Dr. Bin Zhang | Senior Vice President of Clinical Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 17, 2024 | 8-K | Current Report |
May 14, 2024 | 10-Q | Quarterly Report |
May 14, 2024 | 8-K | Current Report |
Apr 24, 2024 | 8-K | Current Report |
Apr 24, 2024 | ARS | Filing |
Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
Apr 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 26, 2024 | 10-K | Annual Report |